Swiss National Bank’s Emergent Biosolutions EBS Stock Holding History

Swiss National Bank’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-98,700	Closed	-$336K	–	2560
2023 Q3	$336K	Hold	98,700	–	–	﹤0.01%	2575
2023 Q2	$725K	Buy	98,700 +1,800	+2%	+$16.7K	﹤0.01%	2453
2023 Q1	$1M	Sell	96,900 -10,300	-10%	-$125K	﹤0.01%	2248
2022 Q4	$1.27M	Hold	107,200	–	–	﹤0.01%	2206
2022 Q3	$2.25M	Sell	107,200 -1,800	-2%	-$50.1K	﹤0.01%	1793
2022 Q2	$3.38M	Sell	109,000 -5,500	-5%	-$188K	﹤0.01%	1563
2022 Q1	$4.7M	Buy	114,500 +8,000	+8%	+$353K	﹤0.01%	1473
2021 Q4	$4.63M	Hold	106,500	–	–	﹤0.01%	1514
2021 Q3	$5.33M	Buy	106,500 +800	+0.8%	+$48.4K	﹤0.01%	1415
2021 Q2	$6.66M	Buy	105,700 +2,700	+3%	+$173K	﹤0.01%	1283
2021 Q1	$9.57M	Buy	103,000 +1,300	+1%	+$133K	0.01%	1022
2020 Q4	$9.11M	Buy	101,700 +700	+0.7%	+$64.2K	0.01%	985
2020 Q3	$10.4M	Buy	101,000 +2,300	+2%	+$248K	0.01%	790
2020 Q2	$7.8M	Buy	98,700 +13,600	+16%	+$1.01M	0.01%	901
2020 Q1	$4.92M	Buy	85,100 +1,200	+1%	+$69.2K	0.01%	946
2019 Q4	$4.53M	Buy	83,900 +1,600	+2%	+$86.8K	﹤0.01%	1221
2019 Q3	$4.3M	Buy	82,300 +1,300	+2%	+$60.6K	﹤0.01%	1184
2019 Q2	$3.91M	Buy	81,000 +2,100	+3%	+$101K	﹤0.01%	1277
2019 Q1	$3.99M	Buy	78,900 +3,700	+5%	+$218K	﹤0.01%	1234
2018 Q4	$4.46M	Buy	75,200 +2,000	+3%	+$129K	0.01%	1060
2018 Q3	$4.82M	Hold	73,200	–	–	0.01%	1139
2018 Q2	$3.7M	Buy	73,200 +12,100	+20%	+$630K	﹤0.01%	1295
2018 Q1	$3.22M	Buy	61,100 +2,400	+4%	+$120K	﹤0.01%	1324
2017 Q4	$2.73M	Buy	58,700 +1,800	+3%	+$75.8K	﹤0.01%	1443
2017 Q3	$2.3M	Hold	56,900	–	–	﹤0.01%	1526
2017 Q2	$1.93M	Hold	56,900	–	–	﹤0.01%	1615
2017 Q1	$1.65M	Buy	56,900 +1,300	+2%	+$39.6K	﹤0.01%	1689
2016 Q4	$1.83M	Hold	55,600	–	–	﹤0.01%	1612
2016 Q3	$1.75M	Sell	55,600 -3,600	-6%	-$105K	﹤0.01%	1599
2016 Q2	$1.67M	Buy	59,200 +3,600	+6%	+$141K	﹤0.01%	1631
2016 Q1	$1.96M	Buy	55,600 +10,600	+24%	+$374K	﹤0.01%	1465
2015 Q4	$1.8M	Hold	45,000	–	–	﹤0.01%	1415
2015 Q3	$1.28M	Buy	45,000 +5,100	+13%	+$168K	﹤0.01%	1599
2015 Q2	$1.31M	Hold	39,900	–	–	﹤0.01%	1611
2015 Q1	$1.15M	Hold	39,900	–	–	﹤0.01%	1698
2014 Q4	$1.09M	Buy	39,900 +1,000	+3%	+$23.8K	﹤0.01%	1680
2014 Q3	$829K	Hold	38,900	–	–	﹤0.01%	1772
2014 Q2	$874K	Buy	38,900 +1,400	+4%	+$32.6K	﹤0.01%	1803
2014 Q1	$948K	Buy	37,500 +7,400	+25%	+$187K	﹤0.01%	1743
2013 Q4	$692K	Hold	30,100	–	–	﹤0.01%	1786
2013 Q3	$573K	Sell	30,100 -1,200	-4%	-$21.4K	﹤0.01%	1847
2013 Q2	$451K	Buy	+31,300	New	+$453K	﹤0.01%	1987

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank's EBS Position: Q4 2023 in Review

Swiss National Bank sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 98,700 shares — an estimated $336K sold.

Swiss National Bank first reported a position in EBS in Q2 2013 and held it in 42 quarters. The position peaked at $10.4M in Q3 2020. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

Swiss National Bank reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
Swiss National Bank sold 98,700 Emergent Biosolutions shares in Q4 2023, an estimated $336K.
Swiss National Bank first reported a position in Emergent Biosolutions in Q2 2013 and held it in 42 quarters.
Swiss National Bank's Emergent Biosolutions position peaked at $10.4M in Q3 2020.
134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.